drugset / Trial / NCT06177015
Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC
RandomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of intermittent use of darolutamide compared to long-term use in combination with ADT and docetaxel in the treatment of mHSPC patients.
Timeline
- Start
- 2023-12-11
- Primary completion
- 2025-12-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Darolutamide | Other / unclassified | 600 mg | — |